CN113784969A - Plk1选择性降解诱导化合物 - Google Patents

Plk1选择性降解诱导化合物 Download PDF

Info

Publication number
CN113784969A
CN113784969A CN202180002576.XA CN202180002576A CN113784969A CN 113784969 A CN113784969 A CN 113784969A CN 202180002576 A CN202180002576 A CN 202180002576A CN 113784969 A CN113784969 A CN 113784969A
Authority
CN
China
Prior art keywords
amino
methyl
group
mixture
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180002576.XA
Other languages
English (en)
Chinese (zh)
Inventor
崔时雨
柳秀熙
柳志勋
孙山河
李和真
金成勋
博厄斯·南
闵任淑
柳惠国
姜锦泳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Uptra Corp
Original Assignee
Uptra Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uptra Corp filed Critical Uptra Corp
Publication of CN113784969A publication Critical patent/CN113784969A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
CN202180002576.XA 2020-03-27 2021-03-27 Plk1选择性降解诱导化合物 Pending CN113784969A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20200037875 2020-03-27
KR10-2020-0037875 2020-03-27
PCT/KR2021/003807 WO2021194318A1 (en) 2020-03-27 2021-03-27 Plk1 selective degradation inducing compound

Publications (1)

Publication Number Publication Date
CN113784969A true CN113784969A (zh) 2021-12-10

Family

ID=77892014

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180002576.XA Pending CN113784969A (zh) 2020-03-27 2021-03-27 Plk1选择性降解诱导化合物

Country Status (6)

Country Link
US (5) US20230203006A1 (enExample)
EP (1) EP3911654A4 (enExample)
JP (2) JP7440940B2 (enExample)
KR (8) KR20210122163A (enExample)
CN (1) CN113784969A (enExample)
WO (4) WO2021194320A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115490675A (zh) * 2022-09-19 2022-12-20 安阳师范学院 季酮酸衍生物及其制备方法与应用
CN116554044A (zh) * 2023-05-16 2023-08-08 上海师范大学 一种无氨基保护的2,6-二异丙基-4-羧基苯胺及其合成方法
WO2024153110A1 (zh) * 2023-01-17 2024-07-25 北京哲源科技有限责任公司 吡唑并喹唑啉类化合物的立体异构体和氘代衍生物及应用
CN119707950A (zh) * 2024-12-24 2025-03-28 无锡市南京大学锡山应用生物技术研究所 一种用于免疫蛋白靶向降解的嵌合体及其制备方法和应用

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3150316A1 (en) * 2019-09-27 2021-04-01 Dana-Farber Cancer Institute, Inc. ERK5 DEGRADING AGENTS USED AS THERAPEUTIC AGENTS IN CANCER AND INFLAMMATORY DISEASES
KR20210122163A (ko) * 2020-03-27 2021-10-08 (주) 업테라 Plk1의 선택적 분해를 유도하는 피라졸로퀴나졸린 유도체 화합물
KR20240035820A (ko) 2021-07-09 2024-03-18 플렉시움 인코포레이티드 Ikzf2를 조절하는 아릴 화합물 및 약학 조성물
WO2023017442A1 (en) * 2021-08-10 2023-02-16 Uppthera, Inc. Novel plk1 degradation inducing compound
CN118475567A (zh) 2021-08-11 2024-08-09 西藏海思科制药有限公司 一种杂环衍生物及其组合物和药学上的应用
CN114380682A (zh) * 2021-10-27 2022-04-22 上海毕得医药科技股份有限公司 一种2,3-二氟-4-甲氧基苯乙酸合成方法
WO2023104195A1 (zh) * 2021-12-10 2023-06-15 正大天晴药业集团股份有限公司 一种异噻唑并[5,4-d]嘧啶类IRAK4抑制剂的制备方法
JP2024546115A (ja) * 2021-12-10 2024-12-17 シャンドン ルイ ファーマシューティカル カンパニー リミテッド プロテインキナーゼ阻害剤及びその製造方法と応用
CN116924929A (zh) * 2022-07-08 2023-10-24 重庆圣华曦药业股份有限公司 一种碘比醇异构体的合成方法
WO2024117789A1 (en) * 2022-11-29 2024-06-06 Uppthera, Inc. Plk1 degradation inducing compounds with increased rigidity
JP2025530757A (ja) * 2023-02-02 2025-09-17 オップテラ インコーポレイテッド 新規ｐｌｋ１分解誘導化合物
KR20250058831A (ko) 2023-10-23 2025-05-02 주식회사 펩토이드 Ｐｌｋ－１의 폴로박스 도메인에 결합하는 저분자 화합물을 함유하는 항암제
WO2025239662A1 (ko) * 2024-05-13 2025-11-20 (주) 업테라 분해 약물-항체 접합체용 plk1 분해 유도 화합물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009042711A1 (en) * 2007-09-25 2009-04-02 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
CN106543185A (zh) * 2016-11-10 2017-03-29 吉林大学 一种靶向泛素化降解plk1和brd4蛋白的化合物及其应用
CN106977584A (zh) * 2017-04-19 2017-07-25 吉林大学 靶向泛素化降解plk1和brd4蛋白的化合物及其应用
WO2020073930A1 (zh) * 2018-10-09 2020-04-16 嘉兴优博生物技术有限公司 靶向蛋白酶降解平台(ted)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006287766B2 (en) 2005-09-06 2010-06-24 Smithkline Beecham Corporation Benzimidazole thiophene compounds as PLK inhibitors
DK2125822T3 (en) * 2006-12-21 2015-01-12 Nerviano Medical Sciences Srl SUBSTITUTED PYRAZOLOQUINAZOLINDERIVATER, process for their preparation and their use as kinase inhibitors
CA2680757A1 (en) * 2007-03-22 2008-09-25 F. Hoffmann-La Roche Ag Substituted pyrimidodiazepines useful as plk1 inhibitors
JP2011527667A (ja) * 2008-06-18 2011-11-04 武田薬品工業株式会社 ハロ置換ピリミドジアゼピン
AR076784A1 (es) * 2009-05-26 2011-07-06 Nerviano Medical Sciences Srl Combinacion terapeutica que comprende un inhibidor de plk1 y un agente antineoplasico
EP3608317A1 (en) 2012-01-12 2020-02-12 Yale University Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase
KR20250127179A (ko) 2014-04-14 2025-08-26 아비나스 오퍼레이션스, 인코포레이티드 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
EP3270917A4 (en) 2015-03-18 2018-08-08 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
EP3302482A4 (en) * 2015-06-05 2018-12-19 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
RU2018120330A (ru) 2015-11-02 2019-12-04 Йейл Юниверсити Химерные соединения, осуществляющие нацеливание для протеолиза, и способы их получения и применения
US20170281784A1 (en) 2016-04-05 2017-10-05 Arvinas, Inc. Protein-protein interaction inducing technology
KR102747905B1 (ko) * 2017-01-31 2024-12-31 아비나스 오퍼레이션스, 인코포레이티드 세레블론 리간드 및 이를 포함하는 이작용성 화합물
AU2018382122B2 (en) 2017-12-13 2021-11-18 Shanghaitech University ALK protein degradation agent and anti-tumor application thereof
KR102127289B1 (ko) * 2018-09-18 2020-06-26 고려대학교 산학협력단 암 세포를 표적화하기 위한 plk 선택적 형광 프로브 화합물 및 이를 포함하는 plk 검출용 형광 센서
CN109879877B (zh) * 2019-03-04 2021-08-10 吉林大学 一种可降解plk1和brd4蛋白的化合物及其应用
KR20210122163A (ko) * 2020-03-27 2021-10-08 (주) 업테라 Plk1의 선택적 분해를 유도하는 피라졸로퀴나졸린 유도체 화합물
WO2023017442A1 (en) * 2021-08-10 2023-02-16 Uppthera, Inc. Novel plk1 degradation inducing compound

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009042711A1 (en) * 2007-09-25 2009-04-02 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
CN106543185A (zh) * 2016-11-10 2017-03-29 吉林大学 一种靶向泛素化降解plk1和brd4蛋白的化合物及其应用
CN106977584A (zh) * 2017-04-19 2017-07-25 吉林大学 靶向泛素化降解plk1和brd4蛋白的化合物及其应用
WO2020073930A1 (zh) * 2018-10-09 2020-04-16 嘉兴优博生物技术有限公司 靶向蛋白酶降解平台(ted)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115490675A (zh) * 2022-09-19 2022-12-20 安阳师范学院 季酮酸衍生物及其制备方法与应用
WO2024153110A1 (zh) * 2023-01-17 2024-07-25 北京哲源科技有限责任公司 吡唑并喹唑啉类化合物的立体异构体和氘代衍生物及应用
CN116554044A (zh) * 2023-05-16 2023-08-08 上海师范大学 一种无氨基保护的2,6-二异丙基-4-羧基苯胺及其合成方法
CN119707950A (zh) * 2024-12-24 2025-03-28 无锡市南京大学锡山应用生物技术研究所 一种用于免疫蛋白靶向降解的嵌合体及其制备方法和应用

Also Published As

Publication number Publication date
WO2021194319A1 (en) 2021-09-30
KR20210122163A (ko) 2021-10-08
WO2021194318A1 (en) 2021-09-30
JP2023171659A (ja) 2023-12-01
JP2022539579A (ja) 2022-09-12
KR20210122164A (ko) 2021-10-08
KR102313753B1 (ko) 2021-10-19
WO2021194321A1 (en) 2021-09-30
KR20210122165A (ko) 2021-10-08
EP3911654A1 (en) 2021-11-24
KR20210150341A (ko) 2021-12-10
US20230158158A1 (en) 2023-05-25
EP3911654A4 (en) 2022-05-11
KR102337029B1 (ko) 2021-12-09
US20230159515A1 (en) 2023-05-25
KR102319264B1 (ko) 2021-11-01
KR20210122162A (ko) 2021-10-08
JP7440940B2 (ja) 2024-02-29
WO2021194320A1 (en) 2021-09-30
KR102313752B1 (ko) 2021-10-19
US20230203006A1 (en) 2023-06-29
KR102529222B1 (ko) 2023-05-08
US12403198B2 (en) 2025-09-02
US11833208B2 (en) 2023-12-05
US20230372498A1 (en) 2023-11-23
US20230104076A1 (en) 2023-04-06

Similar Documents

Publication Publication Date Title
CN113784969A (zh) Plk1选择性降解诱导化合物
AU2021202065B2 (en) Hepatitis B core protein modulators
CN112218859B (zh) 蛋白水解调节剂及相关使用方法
CN115803030A (zh) 用于kras靶向降解的化合物和方法
CN109678859B (zh) 二氢嘧啶类化合物及其在药物中的应用
CN116507326A (zh) 作为glp-1r激动剂的化合物
CN116261458B (zh) Plk1降解诱导化合物
CN108884067B (zh) 可用于治疗癌症和糖尿病的6-杂环基-4-吗啉-4-基吡啶-2-酮化合物
CN105121426B (zh) 吡咯烷gpr40调节剂
WO2018089355A1 (en) Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors
WO2023143352A1 (zh) 一种含氮杂环化合物、其制备方法及应用
CN115232111A (zh) Sos1降解剂及其制备方法和应用
KR20240024848A (ko) 질소 함유 헤테로고리 화합물, 이의 제조 방법 및 이의 응용
TW202409054A (zh) 經取代之咪唑醯胺化合物及其使用方法
CN118076607A (zh) 新型plk1降解诱导化合物
WO2024179529A1 (zh) 取代的三环衍生物及其药物组合物和用途
TW202430515A (zh) 經取代之1-芳基胺基羰基-1’-雜芳基化合物、經取代之1-雜芳基胺基羰基-1’-雜芳基化合物及其使用方法
CN119790057A (zh) 新型plk1降解诱导化合物
WO2023137634A1 (zh) 三并环化合物、其制备、药物组合物及应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination